Camber Pharmaceuticals Launches Generic Naprosyn®

Piscataway, NJ, November 23, 2022– Camber Pharmaceuticals is pleased to announce the addition of Naproxen Oral Suspension to its current portfolio.
Naproxen Oral Suspension is indicated for the relief of the signs and symptoms of:
- rheumatoid arthritis
- osteoarthritis
- ankylosing spondylitis
- polyarticular juvenile idiopathic arthritis
- tendonitis
- bursitis
- acute gout
The management of:
- pain
- primary dysmenorrhea
Naproxen Oral Suspension from Camber is available in 125 mg/5 mL strength in 500 mL bottles.
To find out more about Naproxen Oral Suspension please visit www.camberpharma.com
Camber Pharmaceuticals is a fully integrated pharmaceutical company. Its parent company, Hetero, of Hyderabad, India, is one of the world’s leading API and finished dosage manufacturers. Camber is committed to bringing the highest quality generic pharmaceuticals to consumers, improving quality of life through cost-effective medications.
# # #
If you would like more information about this topic, please contact Megan Little at [email protected]
Recent articles
- Camber Launches 13 New Generic Products in Q1 2025, Sets Ambitious Pace for the Year
- Camber Launches Mycophenolate Mofetil Capsules
- Camber Launches Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution
- Camber’s Triple Play – Featured Generics
- Big Game Commercial
- Charting a Bold Path for 2025